Oxidative stress in patients with Graves' ophthalmopathy: Relationship between oxidative DNA damage and clinical evolution

Eye

Volumn 23, Issue 8, 2009, Pages 1725-1730

  Tsai, C C ^a   Cheng, C Y ^a,b,c   Liu, C Y ^a   Kao, S C ^a   Kau, H C ^a,d   Hsu, W M ^e   Wei, Y H ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Graves' ophthalmopathy; Oxidative DNA damage; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANTITHYROID AGENT; CREATININE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE; ENDOCRINE OPHTHALMOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUTHYROIDISM; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PROTEIN URINE LEVEL; SCORING SYSTEM; SMOKING; URINALYSIS;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CREATININE; DEOXYGUANOSINE; DNA DAMAGE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAVES OPHTHALMOPATHY; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SMOKING; YOUNG ADULT;

EID: 69049086942     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.310     Document Type: Article

References (40)

1. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 2003; 24: 802-835. (Pubitemid 38067700)
2. Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993; 329: 1468-1475.
3. Rotella CM, Alvarez F, Kohn LD, Toccafondi R. Graves' autoantibodies to extrathyroidal TSH receptor: their role in ophthalmopathy and pretibial myxedema. Acta Endocrinol 1987; 281: 344-347. (Pubitemid 17110848)
4. Bahn RS. Pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab 2003; 88: 1939-1946.
5. Smith TJ, Hoa N. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab 2004; 89: 5076-5080. (Pubitemid 39391451)
6. Smith TJ. The putative role of fibroblasts in the pathogenesis of Graves' disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation. Autoimmunity 2003; 36: 409-415.
7. Chen B, Tsui S, Smith TJ. IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy. J Immunol 2005; 175: 1310-1319. (Pubitemid 41095021)
8. Tsai CC, Kau HC, Kao SC, Lin MW, Hsu WM, Liu JH et al. Pulsatile ocular blood flow in patients with Graves' ophthalmopathy. Eye 2005; 19: 159-162. (Pubitemid 40309501)
9. Thornton J, Kelly SP, Harrison RA, Edwards R. Cigarette smoking and thyroid eye disease: a systematic review. Eye 2007; 21: 1135-1145. (Pubitemid 47382137)
10. Pryor WA, Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann N Y Acad Sci 1993; 686: 12-27.
11. Burch HB, Lahiri S, Bahn RS, Barnes S. Superoxide radical production stimulates retroocular fibroblast proliferation in Graves' ophthalmopathy. Exp Eye Res 1997; 65: 311-316. (Pubitemid 27360161)
12. Cawood TJ, Moriarty P, O'Farrelly C, O'Shea D. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrinol Metab 2007; 92: 59-64. (Pubitemid 46067509)
13. Abalovich M, Llesuy S, Gutierrez S, Repetto M. Peripheral parameters of oxidative stress in Graves' disease: the effects of methimazole and 131 iodine treatments. Clin Endocrinol (Oxford) 2003; 59: 321-327. (Pubitemid 37046985)
14. Guerra LN, Ríos de Molina Mdel C, Miler EA, Moiguer S, Karner M, Burdman JA. Antioxidants and methimazole in the treatment of Graves' disease: effect on urinary malondialdehyde levels. Clin Chim Acta 2005; 352: 115-120. (Pubitemid 40093862)
15. Ademoglu E, Ozbey N, Erbil Y. Determination of oxidative stress in thyroid tissue and plasma of patients with Graves' disease. Eur J Intern Med 2006; 17: 545-550. (Pubitemid 44827700)
16. Venditti P, Di Meo S. Thyroid hormone-induced oxidative stress. Cell Mol Life Sci 2006; 63: 414-434.
17. Bednarek J, Wysocki H, Sowinski J. Oxidative stress peripheral parameters in Graves' disease: the effect of methimazole treatment in patients with and without infiltrative ophthalmopathy. Clin Biochem 2005; 38: 13-18. (Pubitemid 39647650)
18. Lu R, Wang P, Wartofsky L, Sutton BD, Zweier JL, Bahn RS et al. Oxygen free radicals in interleukin-1beta-induced glycosaminoglycan production by retro-ocular fibroblasts from normal subjects and Graves' ophthalmopathy patients. Thyroid 1999; 9: 297-303. (Pubitemid 29171781)
19. Bednarek J, Wysocki H, Sowinski J. Peripheral parameters of oxidative stress in patients with infiltrative Graves' ophthalmopathy treated with corticosteroids. Immunol Lett 2004; 93: 227-232. (Pubitemid 38670378)
20. Tsai CC, Kao SC, Cheng CY, Kau HC, Hsu WM, Lee CF et al. Oxidative stress change by systemic corticosteroids treatment of patients with active Graves' ophthalmopathy. Arch Ophthalmol 2007; 125: 1652-1656.
21. Bartley GB, Gorman CA. Diagnostic criteria for Graves' ophthalmopathy. Am J Ophthalmol 1995; 119: 792-795.
22. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 1989; 73: 639-644. (Pubitemid 19202075)
23. Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest 1991; 14: 853-860.
24. Tsai CC, Kau HC, Kao SC, Hsu WM. Exophthalmos of patients with Graves' disease in Chinese of Taiwan. Eye 2006; 20: 569-573. (Pubitemid 43674993)
25. Giacosa A, Filiberti R. Free radicals, oxidative damage and degenerative diseases. Eur J Cancer Prev 1996; 5: 307-312. (Pubitemid 27006987)
26. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007; 121: 2381-2386. (Pubitemid 350022406)
27. Tüzün A, Erdil A, Inal V, Aydin A, Baǧci S, Yeşilova Z et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin Biochem 2002; 35: 569-572. (Pubitemid 35462134)
28. Rajesh M, Ramesh A, Ravi PE, Balakrishnamurthy P, Coral K, Punitham R et al. Accumulation of 8-hydroxydeoxyguanosine and its relationship with antioxidant parameters in patients with Eales' disease: implications for antioxidant therapy. Curr Eye Res 2003; 27: 103-110. (Pubitemid 37041195)
29. Sacca SC, Pascotto A, Camicione P, Capris P, Izzotti A. Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Arch Ophthalmol 2005; 123: 458-463. (Pubitemid 40489915)
30. Kau HC, Tsai CC, Lee CF, Kao SC, Hsu WM, Wei YH. Increased oxidative DNA damage, 8-hydroxydeoxyguanosine, in human pterygium. Eye 2006; 20: 826-831. (Pubitemid 44316994)
31. Koltuksuz U, Uz E, Ozen S, Aydinç M, Karaman A, Akyol O. Plasma superoxide dismutase activity and malondialdehyde level correlate with the extent of acute appendicitis. Pediatr Surg Int 2000; 16: 559-561.
32. Oldenburg B, van Kats-Renaud H, Koningsberger JC, van Berge Henegouwen GP, van Asbeck BS. Chemiluminescence in inflammatory bowel disease patients: a parameter of inflammatory activity. Clin Chim Acta 2001; 310: 151-156. (Pubitemid 32728344)
33. Burch HB, Lahiri S, Bahn RS, Barnes S. Superoxide radical production stimulates retroocular fibroblast proliferation in Graves' ophthalmopathy. Exp Eye Res 1997; 65: 311-316. (Pubitemid 27360161)
34. Hiromatsu Y, Yang D, Miyake I, Koga M, Kameo J, Sato M et al. Nicotinamide decreases cytokine-induced activation of orbital fibroblasts from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 1998; 83: 121-124. (Pubitemid 28498321)
35. Asami S, Manabe H, Miyake J, Tsurudome Y, Hirano T, Yamaguchi R et al. Cigarette smoking induces an increase in oxidative DNA damage, 8- hydroxydeoxyguanosine, in a central site of the human lung. Carcinogenesis (London) 1997; 18: 1763-1766. (Pubitemid 28134683)
36. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84. (Pubitemid 44566469)
37. Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. JAMA 1993; 269: 479-482.
38. Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid-associated ophthalmopathy. Clin Endocrinol (Oxford) 1995; 42: 45-50.
39. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA et al. The treatment of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996; 121: 200-206. (Pubitemid 26055165)
40. Bouzas EA, Karadimas P, Mastorakos G, Koutras DA. Antioxidant agents in the treatment of Graves' ophthalmopathy. Am J Ophthalmol 2000; 129: 618-622. (Pubitemid 30323727)